Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Status

APPROVED_FOR_MARKETING

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT05722912

Enrollment

Unknown

Registered

2023-02-10

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft-versus-host Disease (GVHD)

ruxolitinib, acute or chronic steroid-refractory GVHD, hematopoietic stem cell transplantation (allo-HSCT)

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

DRUGRuxolitinib

Ruxolitinib Cream

Sex/Gender

ALL

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026